NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers

Foot Ulcer, Diabetic Clinical Trial

Official title:

The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02461641
• Other study ID #: RD2014-08-03
• Status: Completed
• Phase: N/A
• Start date: March 2015
• Est. completion date: October 25, 2018

Study information

• Verified date: October 2018
• Source: NuTech Medical, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to determine the heal rate of diabetic foot ulcers at 4 weeks, and complete closure at 8 and 12 weeks of patients treated with either NuShield or Affinity compared to standard care alone.

Description:

This is a three (3)-arm evaluation in 100 patients over 3 facilities with diabetic foot ulcers (DFU). Patients will be treated with NuShield or Affinity together with standard therapy or with standard care alone. For the purposes of this evaluation, standard therapy will consist of extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing, off-loading to decrease pressure on extremity, aggressive treatment of infection and arterial revascularization if indicated. The patients will receive NuShield or Affinity plus standard therapy to determine optimal application method. The evaluation duration is 4 weeks with 8-week and 12-week follow-up visits. Patients with diabetic neuropathic foot ulcers of at least 4 weeks duration and free of clinical signs of infection at the time of treatment may be eligible for inclusion. At Week -1, each patient will undergo aggressive, surgical debridement. The site should be free of fibrin, necrotic and callous tissue. Digital imaging and planimetery of the target ulcer will be performed pre- and post initial debridement and at each subsequent visit as per the evaluation schedule. This evaluation is designed to investigate the potential of an allogeneic placental-derived amniotic membrane to accelerate healing of lower extremity DFU when used in conjunction with standard therapy. This potential will be measured as an increase in the rate of healing (daily decrease in percent wound area/volume compared to initial debrided ulcer area/volume) of patients treated with NuShield or Affinity plus standard wound care compared to patients treated with standard good wound care alone. Studies by Margolis and co-workers have demonstrated that the use of this surrogate marker, measured at 4 and 8 weeks of care, is predictive (>70%) of wound healing in patients with DFU at the 20th week of care. [Kantor 1998; Margolis 2003] The secondary endpoint will be patients achieving complete closure (100%) by week 12.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: October 25, 2018
• Est. primary completion date: April 30, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Subject is or greater than 18 years old.

2. Type 1 or Type 2 diabetes.

3. Subject has plantar ulcers of greater than or equal to 4 weeks duration at presentation, unresponsive to standard wound care.

4. Subject's ulcer size >0.5cm2 and < 20cm2 area post-debridement.

5. Subject has well controlled glucose levels, with HbA1c < 10%.

6. Subject has adequate lower extremity perfusion, with Ankle-Brachial Index > 0.8 (note:

this is an ABI-equivalent, based on biphasic or triphasic color duplex - PVR or MRA. Diabetics often have peripheral vascular calcification or poorly compressible vessels resulting in abnormally high Ankle-Brachial Indices.) or dorsum transcutaneous oxygen test (TcPO2) > 30 mmHg. Presence of tibial and plantar pulses is preferred.

7. Subject should have no evidence of unresolved gross soft-tissue infection or boney pathology (i.e. osteomyelitis).

8. Subject should have no evidence of underlying co-morbid conditions that would adversely affect wound healing such as: Cancer, Raynaud's syndrome, severe venous insufficiency or uncorrected arterial insufficiency, etc.

9. Subject should not be on medications that compromise healing: cytotoxic chemotherapeutics, etc

Exclusion Criteria:

1. Patients with evidence of skin cancer within or adjacent to the ulcer site.

2. Patients who have signs and symptoms of boney pathology (i.e. osteomyelitis) following debridement.

3. Patients with ulcers on the calcaneus.

4. Patients who have significant arterial disease as determined by ABI, duplex Doppler sonography (PVR) or magnetic resonance angiography (MRA): Ankle-Brachial Index < 0.8 (note: this is an ABI-equivalent, based on biphasic or triphasic color duplex - PVR or MRA. Diabetics often have peripheral vascular calcification or poorly compressible vessels resulting in abnormally high ABIs); dorsum transcutaneous oxygen test (TcPO2) < 30 mmHg; absence of tibial or plantar pulses.

5. Patients who have documented clinically significant medical conditions, which would impair wound healing. This includes:

• Renal impairment (creatinine >2.5 mg/dL);

• Hepatic impairment (2XULN);

• Hematological disorders (abnormities of formed elements);

• Neurologic disorders resulting in significant impairment of sensory and motor functions as judged by the investigator;

• Patients with signs and symptoms of cellulitis;

• Patients with ulcers with sinus tracts associated with an ongoing infection;

• Patients with active deep vein thrombosis;

• Patients with uncontrolled diabetes, as demonstrated by increased HbA1C (> 10%);

• Immunocompromised patients (e.g., lymphoma, AIDS, myelodysplastic disorders)

• Patients with a history of basal cell carcinomas or actinically induced squamous cell carcinomas which have been effectively treated are not excluded, except if the skin cancer was in the exact location of the target ulcer.

6. Patients with active systemic cancer receiving active cancer therapy

7. Patients who are currently receiving, or have received within 1 week prior to study entry:

• Adriamycin (doxorubicin), bleomycin, serolimus (Rapamune, rapamycin) and anti-TNFa cytotoxic/immunosuppressive agents;

• Radiation therapy at the ulcer site;

• Topical growth factors at the target site (i.e., Regranex®).

8. Patients enrolled in wound or drug investigational agent study for any disease within the past 4 weeks.

9. Patients previously treated with amniotic membrane, PRP/PRFM, stem cell therapy, Apligraf, OrCel, Dermagraft, Graft Jacket, Oasis, stem cell therapy or any other advanced therapy at the target site for 1 month prior to enrollment.

10. Pregnant or breast-feeding.

11. Patients, who in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Related Conditions & MeSH terms

• Diabetic Foot
• Foot Ulcer
• Foot Ulcer, Diabetic
• Ulcer

Intervention

Other:
• NuShield
NuShield is a sterilized dehydrated amnion chorion membrane patch.
• Affinity
Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
• Standard of Care
Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.

Locations

Country	Name	City	State
United States	Richard C. Galperin, DPM, FAPWCA	Dallas	Texas
United States	Wound Institute and Research Center	Dunmore	Pennsylvania
United States	Limb Preservation Platform	Fresno	California
United States	The Miller Care Group	Indianapolis	Indiana
United States	Futuro clinical Trials, LLC	McAllen	Texas
United States	The Wound Treatment Center	Opelousas	Louisiana
United States	Temple University School of Pediatric Medicine	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
NuTech Medical, Inc	Organogenesis

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean adjusted heal rate	Percentage change in area method using ARANZ camera	4 weeks
Secondary	Extent of wound closure at 12 weeks	Percentage of wound closed at 12 weeks.	12 weeks
Secondary	Length of time to 100% healing of foot ulcer	Time (in days) to 100% healing-- complete closure in the absence of drainage	Up to 12 weeks